Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Cancer Res. 2016 Jun 2;76(15):4525–4534. doi: 10.1158/0008-5472.CAN-16-1040

Fig. 2. Inhibition of DUBs USP14 and UCHL5 by benzyl-4-piperidone compounds.

Fig. 2

(A) CHP100, A673, and TC-71 cells were treated with b-AP15 for 3 h followed by DUB activity labeling. DUB inhibition is indicated by loss of the higher molecular weight USP14-UbVS or UCHL5-UbVS band. (B) CETSA of USP14 following b-AP15 treatment. b-AP15 interacts with USP14 as indicated by increased stabilization at 53°C. Results represent the mean ± SD of 3 independent experiments.